On Aug. 26, 2025, Osivax announced it has secured $19.5 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

The multi-year agreement will support key development activities for Osivax’ lead influenza A vaccine candidate, OVX836, a next-generation, broad-spectrum vaccine designed to provide long-lasting protection against circulating and emerging influenza A strains.

The agreement will fund a range of critical activities, including ongoing clinical development, large-scale trial preparation, and process development to enable manufacturing scale-up. Of the initial award, $11.5 million will support the continued development of the OVX836 candidate, with an additional $8 million for the preparation of a large field efficacy study. The agreement includes potential further funding of options that could fund a Phase 2b trial and CMC scale-up activities.

Developing broadly protective influenza vaccines that can be rapidly deployed during seasonal outbreaks and pandemic emergencies is of growing importance. Osivax’ OVX836 targets the nucleoprotein of the influenza virus, a highly conserved internal antigen, potentially allowing for a universal approach that protects against both current and future virus strains.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response (BARDA).